Free for Members: Immunological Responses to AAV Gene Therapy in Neurological Compartments

Looking to gain a better understanding of mechanisms that mediate humoral and cellular immune responses to AAV gene therapy? Join us for an expert-led session to explore the topic on Wednesday, Nov. 30.

Understanding immune responses to AAV gene therapy may help improve the management of these responses and the therapy’s effectiveness. Given the potential negative impact and the lack of neuronal regeneration, this is especially important for neurological compartments.

During this Insight Series session, we'll hear about updates on the humoral and cellular immune responses, as Allison Keeler-Klunk, PhD, takes us through some innate and adaptive immune responses to AAV gene therapy.

Next, Steven Gray, PhD, will talk about toxicity in the dorsal root ganglia (DRG), which has been highlighted as a significant concern, as well as potential immunological mechanisms that drive toxicity.

Finally, Shari Gordon, PhD, will discuss the management of AAV immune response with a focus on the nervous system, and the implications for redosing.

Registrants and ASGCT members can watch this event on demand following its live airing.

Register Now

About the Speakers

Allison Keeler-Klunk, PhD, is an assistant professor at UMass Chan Medical School. Dr. Keeler-Klunk's lab is currently investigating the immune responses to AAV gene therapy, specifically in clinical trials, as well as novel immunotherapies by cell editing and engineering. 

Steven Gray, PhD, is an associate professor in the department of pediatrics at the University of Texas Southwestern Medical Center. Dr. Gray’s core expertise is in AAV gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system.

Shari Gordon, PhD, is senior director of immunology at AskBio. Dr. Gordon is a viral immunologist with expertise in infectious diseases, antibody therapeutics, and gene therapy.